ALZpath

• Alzheimer's disease target and drug discovery by leveraging multiomics and electronic health data

  Shares or equity, 8 Oct 2026

• Air pollution is associated with sex-specific longitudinal changes in astrocytic and neuroinflammatory processes linked to cognitive decline in Alzheimer's disease at-risk individuals

  Consulting or advice, Grants or research support, Board or leadership role, 1 Oct 2026

• Data‐driven cognitive composites predict Aβ‐related decline and progression to MCI: the ADOPIC study

  Shares or equity, 1 Oct 2026

• Blood-based biomarkers of Alzheimer's disease and neurodegeneration in an indigenous African cohort using both Simoa and NULISA platforms

  Consulting or advice, Board or leadership role, 2 Sept 2026

• Presymptomatic plasma biomarkers in autosomal dominant Alzheimer's disease: sequence and timing

  Consulting or advice, Board or leadership role, 24 Aug 2026

• Regional amyloid accumulation, post-traumatic distress, and intrusive symptoms in cognitively unimpaired older adults at risk for Alzheimer's

  Grants or research support, 18 Aug 2026

• Cognitive components derived from traditional neuropsychological tests and their associations with plasma p-tau217 and p-tau181 in mild cognitive impairment: a multisite analysis

  Consulting or advice, Board or leadership role, 12 Aug 2026

• Prediction of mild cognitive impairment progression using time-sensitive multimodal biomarkers

  Consulting or advice, Fees or honoraria, Board or leadership role, 12 Aug 2026

• Plasma Biomarkers for Neocortical Tau Burden

  Consulting or advice, Fees or honoraria, Board or leadership role, 10 Aug 2026

• Lifestyle and psychosocial protective factors drive healthy aging and modulate inflammatory and metabolic pathways

  Consulting or advice, Board or leadership role, 5 Aug 2026

• Astrocyte reactivity modifies the effects of locus coeruleus norepinephrine-related dysfunction on tau and its impact on cognition

  Consulting or advice, Board or leadership role, 1 Aug 2026

• Predicting continuous amyloid PET levels with CSF and plasma brain-derived p-tau217

  Consulting or advice, Board or leadership role, 1 Aug 2026

• CSF fibrinogen predicts longitudinal Tau accumulation in cognitively unimpaired older adults

  Consulting or advice, Board or leadership role, 1 Aug 2026

• Interpreting p-tau217 on the ward: frailty and plasma biomarkers in acutely admitted older adults

  Consulting or advice, Board or leadership role, 1 Aug 2026

• Multi-modal deep learning and explainable AI for predicting multiple dementia-related neuropathologies from brain MRI, clinical, and genetic data

  Consulting or advice, 27 Jul 2026

• Age-related alterations in plasma biomarkers of relevance to Alzheimer's disease are attenuated in KLOTHO KL-VS heterozygotes

  Consulting or advice, Board or leadership role, 6 Mar 2026

• Identification of distinct and shared biomarker panels in different manifestations of cerebral small-vessel disease through proteomic profiling

  Consulting or advice, Fees or honoraria, 24 Feb 2026

• Unraveling the role of polyamine metabolism in postoperative delirium: insights into biochemical mechanisms and biomarker potential

  Consulting or advice, Board or leadership role, 21 Feb 2026

• Midlife sensory and motor measures among best predictors in parsimonious models of long-term cognitive decline and incidence of cognitive impairment in aging adults

  Consulting or advice, 1 Feb 2026

• Repurposing glucagon-like peptide-1 receptor agonists for the treatment of neurodegenerative disorders

  Shares or equity, 19 Dec 2025

Sources: pubmed.ncbi.nlm.nih.gov

• Plasma p ‐tau217 A+T+ status is associated with accelerated cognitive decline in the African Americans Fighting Alzheimer's in Midlife study

  AAIC 2025 abstract, 8 Jan 2026

• Plasma pTau and GFAP are associated with subjective cognitive decline and memory concerns in the remote, digital Brain Health Registry cohort

  AAIC 2025 abstract, 25 Dec 2025

• Comparison of plasma pTau217 assays on different platforms

  AAIC 2025 abstract, 25 Dec 2025

• Plasma Biomarkers in Diverse Populations

  AAIC 2025 abstract, 25 Dec 2025

• Detecting and monitoring longitudinal pathological and clinical changes of Alzheimer's disease using plasma p ‐Tau217

  AAIC 2025 abstract, 24 Dec 2025

• Predicting PET amyloid positivity in the intermediate plasma p ‐tau217 group

  AAIC 2025 abstract, 23 Dec 2025

• Clinical use of blood ptau217: plasma or serum? The matrix matters

  AAIC 2025 abstract, 23 Dec 2025

• Plasma biomarkers, brain amyloid-beta pathology, and cortical thickness in a non-Hispanic White and Black/African American middle-aged community cohort: The HCP-CoBRA study

  Alzheimer's & dementia : the journal of the Alzheimer's Association, 1 Dec 2025

• Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology

  JAMA neurology, 1 Mar 2024

• Plasma p-tau217, p-tau181, and NfL as early indicators of dementia risk in a community cohort: The Shanghai Aging Study

  Alzheimer's & dementia (Amsterdam, Netherlands), 22 Dec 2023

• Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer's disease pathology

  medRxiv : the preprint server for health sciences, 12 Jul 2023